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Veterinary Parasitology 150 (2007) 104–110AbstractRecent reports of suspected ivermectin (IVM) resistance in Ostertagia ostertagi have highlighted the need for research into the
mechanisms of IVM resistance. However, there are no reports of resistant field isolates of O. ostertagi, which have been
characterized for molecular research. Therefore, an anthelmintic susceptible O. ostertagi population was selected for IVM
resistance by repeatedly exposing the population to subtherapeutic and therapeutic levels of IVM over 10 generations. In each
selection round, a group of calves was infected with the progeny of the previous IVM-selected O. ostertagi population. In the last
selection round a therapeutic IVM dose (0.2 mg/kg BW) only reduced the faecal egg counts by 57% and 65% on days 7 and 14 after
treatment, respectively. In contrast, the therapeutic IVM dose was 100% effective at eliminating the parental IVM-susceptible
isolate.
# 2007 Elsevier B.V. All rights reserved.
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The introduction of ivermectin (IVM) in 1981, a
macrocyclic lactone (ML) which has excellent broad-
spectrumactivity against nematodes and several parasitic
arthropods, opened new markets and new management
options for parasite control. However, the intensive and
frequent use of these anthelmintics has resulted in the
development of ML resistance in several hosts (Geary,
2005; Kaplan, 2004; McKellar and Jackson, 2004). In
small ruminants, anthelmintic-resistant nematodes are
already a serious problemworldwide (Jackson andCoop,
2000). IVM resistance was first reported in Haemonchus
contortus and later in Teladorsagia circumcincta and* Corresponding author. Tel.: +32 92647400; fax: +32 92647496.
E-mail address: peter.geldhof@UGent.be (P. Geldhof).
0304-4017/$ – see front matter # 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetpar.2007.09.004Trichostrongylus colubriformis (Kaplan, 2004). Reports
of ML resistance in nematodes of cattle have been less
common, and the general belief is that resistance is not
yet an important issue in this host (Kaplan, 2004).
However, reports ofML-resistant nematodes in cattle are
emerging in several parts of theworld and resistancewill
probably become more widespread. In recent years, ML
resistance in Cooperia spp. has become increasingly
common in Brazil (Echevarria and Pinheiro, 1999),
Argentina (Anziani et al., 2001; Fiel et al., 2001; Mejia
et al., 2003), New Zealand (Familton et al., 2001;
Loveridge et al., 2003; Vermunt et al., 1996), the US
(Gasbarre et al., 2004) and the UK (Coles et al., 1998,
2001). To date, the first cases of suspected emerging IVM
resistance in O. ostertagi are reported in New Zealand
(Mason and McKay, 2006; Waghorn et al., 2006) and
Argentina (Suarez and Cristel, 2007). These reports have
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the light of these recent findings ML resistance in O.
ostertagi might be more common than currently
recognized. Therefore, it is important to investigate the
increase in resistance alleles before ML resistance in O.
ostertagi is widespread. Due to the lack of sensitive tests,
the detection of anthelmintic resistance is currently not
possible at an early stage. The development of sensitive
molecular tests requires knowledge of themechanisms of
ML resistance, but no resistant field isolates of O.
ostertagi has been characterized for molecular research.
For that reason, the aim of this study was to
experimentally select a laboratory IVM-resistant O.
ostertagi isolate in cattle. In the near future, this IVM-
resistant isolate, derived fromaparental IVM-susceptible
isolate, will be used to examine the mechanisms of ML
resistance in O. ostertagi in cattle.
2. Materials and methods
2.1. Parasite isolates
The anthelmintic susceptible parental O. ostertagi
population was initially isolated from a commercial
Belgian dairy farm in 1987 and stored in liquid nitrogen
until 1993. Thereafter the population was maintained in
the laboratory by passage through helminth-free calves.
2.2. Experimental trial design
An anthelmintic susceptible O. ostertagi population
was selected for IVM resistance by repeatedly exposing
the population to subtherapeutic and therapeutic levels
of IVM over 10 generations. For each trial helminth-
free Holstein-cross-breed calves between 5 and 8Table 1
Overview of the sequential selection rounds: the number of calves per selectio







AUC of IVM plasma
(ng day ml1) (S.D.)
Redu
on da
1 4 0.0125 13.7 (1.9) 94.9
2 6 0.025 30.7 (9.9) 94.5
3 5 0.05 74.3 (33.5) 100 (
4 4 0.075 52.9 (20.0) 76.1
5 4 0.1 87.3 (42.1) 99.2
6 3 0.1 86.8 (35.7) 70.5
7 3 0.1 98.1 (19.6) 89.0
8 5 0.2 111.1 (48.8) 90.0
9 6 0.2 252.9 (58.2) 87.8
10 6 0.2 149.4 (34.9) 57.2
a In the last three selection rounds (0.2 mg/kg BW IVM) the calves were e
abomasum.months old were orally infected with 50,000 infective
larvae (2 25,000 L3 in 10 ml tap water). The calves
were fed maize silage and hay ad libitum and had free
access to drinking water.
In the first selection round sixteen helminth-free
calves, infected with the parental IVM-susceptible O.
ostertagi isolate (IVMS), were randomized over four
groups of four animals based on their egg counts on day
25 post-infection. The animals were weighted twice
(days 24 and 25 post-infection) with a balance
calibrated with an accuracy of 1 kg. On day 25 after
infection each group of calves was treated subcuta-
neously with a different subtherapeutic IVM dose (0.1,
0.05, 0.025 and 0.0125 mg/kg Ivomec Merial1) to
assess the efficacy of IVM against the IVMS isolate.
The IVM dose was calculated based on the mean weight
of all the animals on days 24 and 25 post-infection.
Blood samples were collected from each calf on 2, 5 and
10 days post-treatment to determine the IVM plasma
levels. Faecal egg counts (FEC) were performed on day
25 after infection and weekly (on 7, 14, 21 days) after
IVM treatment. To obtain the infective third-stage
larvae (L3) for the next generation, the total faecal
output of the group of calves which gave the desired egg
count reduction (<95% FEC reduction for the first
selection round) was collected from days 3–21 post-
treatment and cultured. Infective L3 were collected
using baermannisation. The L3 progeny of the first five
and the eight selection rounds was passaged through a
helminth-free calf to produce sufficient infective larvae
for the sequential selection round. For each sequential
selection round, a group of calves was infected with the
progeny of the previous IVM-selected O. ostertagi
isolate (2 25,000 L3 in 10 ml tap water) (Table 1). The
IVM doses gradually increased from 0.0125 to 0.2 mg/n round, the IVM doses, area under the curve (AUC value) of the IVM
on days 7, 14 and 21 post-treatment
ction in FEC
y 7 (%) (range)
Reduction in FEC
on day 14 (%) (range)
Reduction in FEC
on day 21 (%) (range)
(93–98) 88.2 (71–94) 93.1 (86–98)
(79–100) 93.4 (79–100) 86.8 (79–100)
100–100) 99.5 (98–100) 100 (100–100)
(50–100) 70.0 (0–100) 56.9 (0–100)
(98–100) 99.3 (98–100) 99.1 (98–100)
(25–96) 65.9 (25–91) 81.3 (50–99)
(71–98) 88.8 (70–98) 81.5 (50–98)
(50–100) 79.5 (0–100) NDa
(50–100) 91.6 (75–100) NDa
(0–92) 65.4 (0–94) NDa
uthanized on day 17 to collect the adult Ostertagia ostertagi from the
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Fig. 1. Schematic diagram of the experimental selection for IVM resistance in Ostertagia ostertagi.kg body weight (BW) over ten generations (Fig. 1) until
an efficacy of <90% with the therapeutic dose (0.2 mg/
kg BW) was reached.
In the last selection round a controlled efficacy test
was conducted. Twelve helminth-free calves were
randomly divided in two groups. One group was
infected with the parental IVMS isolate and onewith the
progeny of the IVM-resistant (IVMR) isolate from
selection round nine. The two groups were treated
subcutaneously with the therapeutic IVM dose on day
25 post-infection to assess the efficacy of IVM against
the IVMS and IVMR isolates. The IVM dose was
calculated based on the mean weight of all the animals
on days 24 and 25 post-infection. Faecal samples and
blood samples were collected as described above.
Individual faecal cultures were made on day 25 post-
infection and days 7 and 14 post-treatment. The two
groups of calves were euthanized on day 17 after
treatment and the O. ostertagi were collected from the
abomasum.
2.3. Pharmacokinetic analysis
In each selection round the IVM levels of all the
calves were analyzed in plasma samples collected on
days 2, 5 and 10 after IVM treatment. All the blood
samples were centrifugated at 3000  g for 15 min and
plasma was stored at 20 8C until analysis. The IVM
plasma concentrations were determined by high
performance liquid chromatography (HPLC) with
automated solid phase extraction and fluorescence
detection according to a previously described method
(Alvinerie et al., 1993; Lifschitz et al., 2000). The limit
of quantification of the IVM analysis method was
0.1 ng/ml and the coefficient of variation was 3.5%. The
areas under the concentration–time curves (AUC) for
IVM in plasma were calculated by the linear trapezoidalrule and expressed as ng day ml1. A Spearman rank
correlation test was used to assess the relationship
between the administered IVM dose and the bovine
plasma concentration of IVM (AUC). Probability (P)
values <0.01 were considered to indicate significant
correlations.
2.4. Efficacy of ivermectin
The faecal egg output was determined using a
modified McMaster technique (Thienpont et al., 1979)
combined with the Cornell-Wisconsin technique
(Egwang and Slocombe, 1981) with a sensitivity of
12.5 eggs per gram (EPG). The percentage efficacy of the
IVM treatment was assessed by the new individually
based faecal egg count reduction test (FECRT) proposed
byCabaret andBerrag (2004). Thismethod is basedon an
individual evaluation of the egg counts before and after
treatment without untreated controls and where each calf
serves as its own control. The equation of the formula
used to determine the percentage reduction in FEC is:
iFECRT ¼ ð1=nÞP 100ð1 ½Ti2=Ti1 Þ, where Ti2 is
post-treatment andTi1 is pre-treatment egg count in host i
from a total n calves. IVM resistancewas defined as a less
than 95% reduction in FEC post-treatment (Coles et al.,
1992, 2006). As noted above, the relationship between
the IVM efficacy and the bovine plasma concentration of
IVM (AUC) was assessed. Probability (P) values <0.05
were considered to indicate significant correlations.
In the last selection round the IVM efficacy was also
assessed by the reduction in larval counts and by the
worm counts of the treated IVMS- and IVMR-infected
calves. To assess the reduction in larval counts 1.5% of
the larval cultures (day 25 post-infection, days 7 and 14
post-treatment) of each calf was counted and the same
formula as for the FECRTwas used. The two groups of
calves were euthanized on day 17 after treatment.
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Fig. 2. The individual bovine plasma concentration of ivermectin after subcutaneous administration.Necropsy, abomasal washing and abomasal digests
(HCl–pepsin) were done according to standard techni-
ques (Ritchie et al., 1966; MAFF, 1986). The total O.
ostertagi worm burdens were estimated by counting 2%
of the abomasal washings and digests of each calf.
3. Results
In the first selection round, the treatment with the 0.1
and 0.05 mg/kg IVM against the IVMS isolate was
100% effective on days 7, 14 and 21 post-treatment. O.
ostertagi eggs were only recovered after treatment with
the two lowest IVM doses. The 0.025 mg/kg IVM
reduced the FEC by 98%, 99% and 100% on days 7, 14
and 21, respectively. The reduction in FEC with
0.0125 mg/kg BW IVM dose was 95%, 88% and
93% on days 7, 14 and 21, respectively. The larvae that
survived the 0.0125 mg/kg BW IVM dose were used for
further selection (Table 1).
The treatment efficacies on days 7, 14 and 21 in the
sequential selection rounds are summarized in Table 1.
In the 10th selection round a controlled efficacy test
was conducted. The treatment with the therapeutic IVM
dose (0.2 mg/kg BW) was 100% effective against the
IVMS isolates since no eggs were detected in the faeces
on days 7 and 14 after treatment and noworm burdens in
the abomasum were found in the treated IVMS animals.
For the IVMR isolate, IVM reduced the FEC by 57%
and 65% at days 7 and 14 post-treatment, respectively.
All the treated IVMR-infected calves had O. ostertagi
worm burdens ranging from 50 to 4800, with a
geometric mean of 590. The efficacy of IVM against
the IVMR isolate, based on the pre- and post-treatment
larval counts was 89% and 59% on days 7 and 14 post-
treatment, respectively. In contrast, the reduction inlarval counts for the IVMS isolate was 100% confirming
the IVM-susceptibility of the parental IVMS O.
ostertagi isolate.
The mean AUC values for the IVM plasma
concentration are presented in Table 1. A significant
correlation was observed between the administered
IVM doses and the IVM plasma concentrations
(R = 0.844, P < 0.01) in the 10 passages. However,
large individual variations in the IVM plasma con-
centrations were present within the same treatment
doses (Fig. 2). In the selection rounds with the
therapeutic treatments the mean AUC value for IVM
varied from 111.1 to 252.9 ng day ml1 for the IVMR-
infected calves (Table 1). In the IVMR-infected calves
of the controlled efficacy test a significant positive
correlation (R = 0.771, P < 0.05) was demonstrated
between the IVM plasma concentration (AUC value)
and IVM efficacy on day 7 post-treatment. However, no
significant correlation was found on day 14 post-
treatment (R = 0.714, P > 0.05). The IVMS-infected
calves treated with the therapeutic IVM dose had a
mean AUC value for IVM of 138.3 ng day ml1 and
showed a similar individual variability (S.D. 2  0.4).
4. Discussion
In the present study an IVM-susceptible O. ostertagi
population was selected for IVM resistance by
repeatedly exposing the population to subtherapeutic
and therapeutic levels of IVM over 10 generations.
While IVM was 100% effective against the susceptible
IVMS O. ostertagi isolate, the efficacy against the
resistant IVMR O. ostertagi isolate was 57% and 65%
on days 7 and 14 post-treatment, respectively. These
results were supported by the adult worm burdens.
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abomasum of IVMR-infected calves, but no adult
worms were found in IVMS-infected calves.
Surprisingly, a large individual variability in IVM
efficacy (0–92%) was demonstrated in the IVMR-
infected calves in selection round 10. Several studies
have described a strong relationship between the
efficacy of ML’s and the drug concentration (Lanusse
and Prichard, 1993; Baggot and McKellar, 1994).
Furthermore, the plasma concentration is closely related
to the IVM concentration in the target tissues such as the
abomasum (Lifschitz et al., 2000; Lespine et al., 2005).
Therefore, it is possible that the individual variability in
efficacy in the last selection round is caused by the
individual variability in IVM concentrations. In con-
trast, despite a similar variability in the AUC value for
IVM in the IVMS-infected calves, treatment with the
therapeutic dose was 100% effective in all the calves.
Although a significant correlation was observed
between the administered IVM doses and the IVM
plasma concentrations, large variations in plasma
concentration were present within the same treatment
doses. A similar pharmacokinetic variability in the IVM
plasma profiles has also been observed in other studies
(McKellar and Benchaoui, 1996; Lanusse et al., 1997)
and can be attributed to differences in breed, the site of
IVM injection (muscle or fat tissue), the extent and rate
of absorption, availability of the drug, metabolism and
body composition, diet intake and body condition
(Hennessy and Alvinerie, 2002).
Despite the fact that IVM resistance can be induced
in O. ostertagi, as shown in the present experiment,
there are very few reports on IVM resistance in O.
ostertagi in the field. The basic population biology of O.
ostertagi and the selection pressure are likely to play an
important role in this (Coles, 2002). The most important
reason for the slow development of anthelmintic
resistance in cattle is considered to be the lower
treatment frequency needed for adult cow, compared to
ewes, and the consequent presence of a source of
refugia. The selective treatment of only first year calves
and the natural resistance of adult cows to nematodes
have resulted in a very low level of treatment. For that
reason the refugia consist primarily of susceptible
worms from untreated second year and older animals. In
addition, infective O. ostertagi larvae can overwinter in
large numbers on the field, which results in a large
refugium in the spring and therefore resistance is likely
to develop much slower compared to sheep nematodes
such as H. contortus. Moreover, under usual field
conditions, adult O. ostertagi worms only survive for a
relatively short period (25–50 days) and produce lessegg compared to C. oncophora in cattle and H.
contortus in sheep. Therefore O. ostertagi worms that
survive the treatment could have a relatively small
advantage over susceptible worms. In contrast, adult H.
contortus in sheep can persist for many months giving a
large advantage to resistant worms to produce the next
generation (Coles, 2002). In addition, the IVM
concentration that O. ostertagi experiences in the
abomasal mucosa is higher than in the intestine, the
target site of C. oncophora (Lifschitz et al., 2000). This
is likely to be the reason why C. oncophora is the dose-
limiting species (Coles, 2002). It was therefore
expected that C. oncophora would be the first genus
showing ML resistance in cattle (Coles, 2002).
On the other hand, the apparent lack of anthelmintic
resistance in O. ostertagi can also be explained by the
lackof sensitivedetection tests (Coles, 2002).To date, the
detection of anthelmintic resistance in field surveys is
mainly based on the in vivo FECRT (Coles et al., 1992).
Martin et al. (1989) demonstrated that the FECRT only
detects benzimidazole (BZ) resistance when the fre-
quency of the resistance alleles is greater than 25% in a
population. Although the genetic basis of ML resistance
and consequent the detection level is different from BZ
resistance, the FECRT most likely detects IVM
resistance only when the frequency of the resistance
alleles is high and significant treatment failure occurs.
The lack of sensitive tests means that the detection of
anthelmintic resistance is not possible at an early stage
and we are not able to follow the spread of resistance
alleles. However, the development of sensitive and
reliablemolecular diagnostic tests requires knowledge of
the mechanisms of resistance and this is currently
lacking. Therefore a good starting point for further
investigation would be to compare the molecular
background of the IVM-susceptible parental isolate
and the laboratory IVM-resistant O. ostertagi isolate in
order to understand better the mechanisms of IVM
resistance inO. ostertagi. Candidate genes that have been
associated with ML resistance in other trichostrongylid
nematodes will be analysed in O. ostertagi.
One should also take into account that a laboratory-
selected isolate not necessarily reflects a resistant field
O. ostertagi isolate. Different selection protocols can
select for different resistance phenotypes and, pre-
sumably, genotypes (Gill et al., 1998). It is likely that
selection with doses below the recommended dose rate
tends to reveal all the potential resistance-associated
genes, but fails to distinguish which gene might have the
largest effect in field-selected resistance (Prichard,
2001; Gilleard and Beech, 2007). Another issue that
needs to be considered is the possibility that different
A.M. Van Zeveren et al. / Veterinary Parasitology 150 (2007) 104–110 109isolates of O. ostertagi may have different mechanisms
of resistance. It will therefore be important to validate
results obtained with the laboratory-selected isolate
against resistant isolates from the field.
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